• Join
  • Login
  • Contact

Search abstracts

Transdermal Buprenorphine: utilization trends in United Kingdom primary care practice

  • At: 2012 FIP Congress in Amsterdam (the Netherlands)
  • Type: Presentations + Posters
  • By: ZIN, Che Suraya (The University of Nottingham, Division for Social Research in Medicines and Health, Nottingham, United Kingdom)
  • Co-author(s): Chen, L. (Division for Social Research in Medicines and Health,, Nottingham, United Kingdom)
    Knaggs, R. (kulliyyah of Pharmacy, International Islamic University Malaysia, Nottingham, United Kingdom)
  • Abstract:

    Background information:Transdermal buprenorphine low doses (5, 10 or 20 µg/hour for 7 days) and the high doses (35, 52.5 or 70 µg/hour for 4 days) are increasingly being used for the treatment of chronic cancer and noncancer pain. Although these formulations have shown better persistence with therapy, there is limited data available on factors


  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 4 October 2019

FIP Congresses